Professional Documents
Culture Documents
Ans: b
Ans: a
Ans: c
Ans: d
Ans: c
6. The biological factor influencing the design and act of controlled release product is
Ans: b
7. Drugs with ---------therapeutic index are unsuitable for incorporation in controlled release
formulation
Ans .b
Ans: b
Ans: b
Ans: d
Ans: b
Ans: d
13. The duration of action of parental controlled release systems can be extended up to what
time?
Ans: d
14. Drug having molecular weight ------------------ is good candidate for controlled release
dosage form
a) More than 2000 dalton b) Less than 600 dalton c) Over and above 1000 dalton
Ans: b
15. What does the polymer coating of diffusion controlled release tablet do for its release
b) Has low solubility low permeability and ph independent swelling which allows diffusion of the
drug (water diffuses in and drug diffuses out)
Ans: b
16. The absorption of the ophthalmic drug does not depend on which of the following?
Ans: d
a) Drugs with very short half-lives b) Drugs with narrow therapeutic indices
Ans: d
Ans: d
Ans: d
Ans : d
22. One of the following polymer type is not classified on the basis of its application &
properties
Ans: d
23. Ideally, the drug should have half-life to be formulated in controlled release dosage
Ans: a
24. Floating drug delivery dosage forms are prepared by using following polymer
(a) Gelatin (b) HPMC (c) EC-Ethyl cellulose (d) MC-Methyl cellulose
Ans: b
Ans: c
a. Fick's law of diffusion b. Noyes Whitney equation c. Zero order d, First order
Ans: b
c) Can get easily precipitated in the injection site d) Rapid onset but fast excretion
Ans: b
Ans: d
Ans: d
Ans: b
31. The drugs of delayed release systems are those that are
a. absorbed from a specific intestinal site b. meant to exert local effect at a specific GI site
Ans: d
Ans: d
Ans-: a
34. Find one of the following which should not be a characteristic of the vehicles or polymers
which are used for parenteral formulations
Ans: b
36. Dosage form that have drug release features based on time course and location which are
designed to accomplish therapeutic objective not offered by conventional are:
a. Immediate release b. Modified release c. Diffusion mediated release d. All the above
Ans:-b
37. Ion activated DDS is ----------- type of activated systems
39. For a drug to be formulated in to controlled/modified release dosage form it’s Margin of
safety should be----
a. Very low b. Very high c. Normal d. None of above
Ans:-b
40. Immediate release drug delivery system lacks which of the following characteristics
Ans:-d
43. Dissolution of drugs depend upon
a. Thickness of diffusion layer b. Surface area of the exposed solid
c. Saturated solubility of the drug d. All of the above
Ans:-d
44. Controlled drug delivery system provides the concentration of drug to the absorption site
Ans: a
Ans: b
Ans: b
a- hydoxy ethyl cellulose b- hydoxy methyl cellulose c- methyl cellulose d- hydroxy propyl
cellulose
Ans: a
Ans: b
BCDA COLLEGE OF PHARMACY &TECHNOLOGY
Hridaypur, Barasat, Kolkata -700127
Ans: d
Ans: b
Ans: d
Ans: d
Ans: c
Ans: c
7. The Oral cavity has been used as a site for ___________drug delivery.
Ans: c
Ans: b
Ans: d
Ans: a
Ans: b
a) Acidic drugs and lipophilic drug b) Lipophilic drugs and neutral drugs
c) Neutral drugs and lipophilic drugs d) Lipophilic ,neutral and basic drugs
Ans: a
22. The maximum capsule size & shape for convenient oral use in human is
Ans: d
a) Release the drug along the entire length of GIT b) Prolonged their residence in the GIT &
release c) Usage of bioadhesive polymer d) Use of high or low density pellets.
Ans: c
Ans: b
26. Device containing pilocarpine and alginic acid in a drug reservoir is used in
Ans: b
Ans: b
Ans: c
30. So many difficulties are observed during microencapsulations process. The incorrect
answer is
Ans: d
31. The layer described as translucent and viscid secretion which forms a thin continuous
gel blanket adherent to the mucosal epithelial surface
Ans: a
Ans: b
Ans: a
Ans: b
a) Water insoluble resin b)Water soluble resin c)Wax and lipid d)Enteric coating resin
Ans: c
a) prolonged release b) Reduce gastric irritation c)Taste masking d)None of the above
Ans: d
37. Following can be considered as physico-mechanical technique used for
microencapsulation
Ans: c
Ans: d
Ans: c
Ans: d
a. water soluble resin b. water insoluble resin c. enteric coated resin d.wax resin
Ans: c
Ans: c
Ans: c
Ans : c
Ans: a
a. Release the drug along the entire length of GIT b. Prolonged their residence in the GIT
Ans: c
47. Goblet cells or salivary glands secretes ------- directly onto the epithelial surfaces
Ans: b
a. Bind together code of action b. Using single interface for general class of actions.
Ans: a
Ans: d
Ans : c
51. Drug release rate from microcapsules conforming to reservoir type is
a) first order b) slow first order c) zero order d) none of the above
Ans : c
Ans: d
Ans: c
Ans: b
a) Buccal and nasal b) Buccal and In muscular c) Sublingual and nasal d) Buccal and sublingual
Ans: d
BCDA COLLEGE OF PHARMACY &TECHNOLOGY
Hridaypur, Barasat, Kolkata -700127
Ans: c
Ans: a
3. First transdermal patch approved in 1979 was for the following drug
Ans: b
Ans: b
Ans: a
6. The rate at which monolithic devices transfer drugs to the patient body is proportional to
____of time.
a. Square of time b. The square root of time c. Twice the time d. Half the time
Ans: b
c. Drugs with narrow therapeutic index d. Drugs which are metabolized in the skin
Ans: c
Ans: d
Ans: b
Ans: a
Ans: d
a) Quick stick test b) probe tack test c) skim peel test d) thumb tack test
Ans:c
Ans: d
14. Silicone, Polybutyl acrylate, polyisobutylene are examples of
Ans: d
15. Well developed “intercellular lipid lamellae” is a feature of which layer of the
epithelium.
Ans: d
Ans: c
Ans: d
Ans: a
a) Drugs with very short half-lives b) Drugs with narrow therapeutic indices
Ans: d
Ans: d
Ans: b
Ans: b
Ans: a
24. Most of the drugs get absorbed through the skin by the following mechanism
Ans: b
Ans: a
26. Floating microspheres are gasto retentive drug delivery systems based on ______
approach
Ans: b
Ans: c
28. Bile salts like sodium deoxycholate, sodium glycocholate are used in nasal drug delivery
system as
Ans: a
29. Following is the rate controlling barrier evaluated for transdermal application
Ans: a
Ans: a
31. Hollow microspheres are a non effervescent approach for GRDDS are also known as
Ans: b
Ans: a
33. Followings are the materials commonly used for bioadhesion except
Ans: b
34. The aerosol medication particles must be of _____ size for inhalation and deposition in
the airway.
Ans: a
Ans: c
37. The ideal molecular weight for the drug for Transdermal drug delivery system is_____
a) Not more than 800 Dalton b) Not more than 1000 Dalton
c) Not more than 400 Dalton d) Not more than 1200 Dalton
Ans: c
Ans: b
39. In nasopulmonary drug delivery system the absorption can be enhanced by which of
the following approaches
Ans: a
Ans: a
Ans: c
42. Hollow microspheres are a non effervescent approach for GRDDS are also known as
Ans: b
43. Following drugs cannot be given as transdermal administration
a) Drugs with very short half-lives b) Drugs with narrow therapeutic indices
Ans : d
Ans: a
45. From the following anatomical structure the drugs from TDDS enter the systemic
circulation
Ans: b
Ans: c
a. Passive targeting b. Active targeting c. Second order targeting d. Smart drug delivery system
Ans. d
c) Control drug release by partitioning the drug from the oil d) Administration of emulsions
Ans: a
a) mobility pattern of stomach b)gastric emptying c) mixing of food d) all of the above
Ans: a
51. Drug eluting stents are the best example of TDDSs for
Ans: a
52. Backing membrane, Control membrane, Matrix polymer, Adhesive layers are
components of
Ans: b
53. In Nasopulmonary drug delivery systems the absorption can be enhanced by following
approaches
Ans: d
Ans: a
Ans: c
a) DPIs are small devices b) Liberation of powders from the device and segregation of particles
Ans: b
BCDA COLLEGE OF PHARMACY &TECHNOLOGY
Hridaypur, Barasat, Kolkata -700127
Ans: d
Ans: d
Ans: a
Ans: d
Ans: d
Ans: d
7. In nanoparticle technology, LDC stands for
Ans: d
Ans: b
Ans: a
Ans: d
Ans: b
Ans: b
19. A monoclonal antibody(mAb or moAb) is an antibody made by cloning a unique__
a) RBC b) Calcium c) WBC d) serum
Ans: c
20. Liposome contains oil soluble material in ___ cavity.
a) polar b) hydrophilic c) neutral d) non polar
Ans: d
21. Liposome are spherical structure usually between _____ in diameter.
a) 80-100nm b) 60-100nm c) 55-100nm d) 15-1000nm
Ans: d
22. Liposomes were discovered by
Ans: a
Ans: a
24. The analytical techniques used in the characterization of cholesterol auto oxidation and
anti oxidation degradation studies in Liposomes
Ans: d
25. The approach in which the carrier molecule has therapeutic activity and thus increase
the therapeutic effect of drug is called
Ans: c
Ans: b
Ans: b
29. Nanomaterials differ significantly from other materials due to the following reason
Ans : c
b)To achieve the site-specific action of the drug c)Both a) and b) d)None of the above
Ans : c
Ans: a
Ans: c
Ans: a
Ans: c
Ans: a
Ans: c
Ans: a
38. The terms FATMLV, SPLV, VET, DRV etc. are associated with
Ans: b
Ans: d
Ans: c
41. Liposomes , lipid particles and polymeric mecellers belong to class of carrier
a. Soluble carriers b. cellular carriers c. Particle carriers d. None of above
Ans: c
Ans: b
Ans: d
Ans: b
45. The rate at which monolithic devices transfer drugs to the patient body is proportional to
_____of time.
a) Square of time b) The square root of time c) Twice the time d) Half the time
Ans: b
a. Biochemically inert b. chemically and physically stable in vivo and in vitro conditions
Ans: d
a) Modified release formulations are most useful for drugs with a long half-life
Ans: a
48. The following methods are used for the purification of nanoparticles
Ans : d
Subject: B. Pharm
Code: PT - 716B
GROUP I
Ans: c
14. Menorrhagia is the side effect of Intra Uterine Devices in which there is
a. Prolonged bleeding b. Painful menstrural periods c. Shorter menstrural cycle d. None of the
above
Ans: a
15. Example of barrier method of contraception include?
Ans: b
Ans: a
Ans: d
Ans: a
a. Soft Ocular Drug Inserts. b. Superoxide dismutase c. Soluble Opthalmic Drug Inserts. d.
Soluble Ocular Drug Implant.
Ans: c
Ans: b
Ans: c
a. 20 micrograms per day b. 20 micrograms per hour c. 200 micrograms per day d. 0.2
micrograms per day
Ans: a
Ans: d
GROUP II
28. Thick muscular middle layer made up of bundles of smooth muscle embedded
connective tissue is-
a) Peritoneum b) Myometrium c) Endometrium d) all of the above
Ans:b
30.The levonorgestrle IUD/LNG IUDs release the hormone at an approximate rate of-
a) 20microgram per hour b) 20microgram per day c) 200 microgram per day d) 0.2 microgram
per day
Ans:b
Ans:c
GROUP III
Ans: c
Ans: d
Ans: a
Ans: a
Ans: b
Ans: b.
a) First generation IUDs. b) Second generation IUDs. c) Third generation IUDs. d) All the
above.
Ans: c.
Ans: a)
Ans: a
Ans: d
Ans. B
Ans: b
Ans: b
Ans : d
50. Followings are the first generation plastic intrauterine devices, except _____
Ans: a
51. Cul-de-sac is the site of insertion for following occular drug delivery system-
Ans: d
Ans: c
Ans: c
54. The following statements are true about Intrauterine devices (IUD) except:
b) The pregnancy rate of Lippes loop and Cu—T 200 are similar
Ans: a
Ans: c
Ans: b
Ans: a
GROUP IV
59.which of the following conditions can be deliberated as category 4 for IUD placement according to
WHO?
Ans : d
Ans-d
a) Minipill
b) Condoms
c) Progestasert
Ans-b
a. 1890
b. 1909
c. 1920
d. 1960
Ans-b
a. Menstrual bleeding
Ans - d
Answer:a
a) Solution
b) Liniment
c) Suspension
d) Ointment
Ans: b
a)Niosome
b)Liposome
c)Ribosome
Ans - a
GROUP V
Ans: b
(a) Blurring of vision (b) Drug stability (c) Drug choice flexibility (d) All of the above
Ans: a
Ans: b
a) Soft ocular drug inserts b) Superoxide dismutase c) Soluble ocular drug inserts d) Soluble
ocular drug implant
Ans – c
Ans: c
77. The part of the eye is responsible for the function ‘Refracts Light Rays’:
Ans : d
a) Lysosomal activation
b) Lysosomal inactivation
c) Fertilization
Ans: a